ZIVO Bioscience and Leading Global Animal Health Company to Advance ZIVO’s Immune-Enhancing Compounds in Poultry
Initially, ZIVO and its partner have executed two agreements that will govern independent studies designed to validate and expand the use of ZIVO’s proprietary actives as immune-enhancing biologics to complement existing poultry vaccination strategies.
The first agreement covers a 42-day study focused on coccidiosis, a parasitic disease that remains a major challenge to poultry producers worldwide. This challenge study is intended to confirm previously demonstrated effects of ZIVO’s compound now co-administered with the collaborator’s vaccine, and will include collecting tissue and plasma samples to evaluate performance parameters not previously examined. This trial will support the regulatory approval process of the USDA’s Center for Veterinary Biologics, as well as to validate the commercial business case and lead to a commercial agreement.
Under the second agreement, a study will assess ZIVO’s compounds using a model of various viral diseases of significant consequence to the commercial poultry industry. The particular disease to be studied, which has no cure, is characterized by rapid onset and high mortality rates. The virus was selected for its well-established in vivo model, clear clinical endpoints and short study duration, while serving as a representative model for a range of other viral poultry diseases.
This study was prompted by ZIVO’s previously reported data showing reduced severity and spread of low-pathogenic avian influenza (LPAI) in treated birds. Positive outcomes from this trial will lead to a broader research agreement to pursue additional diseases. Applications for treating viruses represent a significant expansion of the therapeutic range and economic value of ZIVO’s novel immune-boosting compounds.
Both studies, to be fully funded by the collaborating company, will investigate several ZIVO product candidates for their ability to:
- Reduce the time between immunization and the onset of protective immunity,
- Protect birds during the vulnerable period between vaccination and immunity,
- Enhance the immune response following immunization, and
- Mitigate the immunosuppressive effects of diseases that leave birds susceptible to secondary infections.
“This collaboration supports our strategy to partner with a major animal health company that brings scientific expertise and R&D infrastructure to advance our innovations to global markets efficiently and at scale,” said John Payne, Chairman and Chief Executive Officer of ZIVO Bioscience. “We are aligned with this company on the broad applicability of our immune-modulating technology and its potential to create a disruptive, non-antibiotic therapeutic platform. Adding ZIVO’s therapeutic products to their portfolio would represent an entirely new market for our partner, and the significant prior work we’ve done provides high confidence for success.”
About ZIVO Bioscience
ZIVO Bioscience, Inc. is a research and development company with an intellectual property portfolio comprised of proprietary algal and bacterial strains, biologically active molecules and complexes, production techniques, cultivation techniques and patented or patent-pending inventions for applications in human and animal health. Please visit www.zivobioscience.com for more information.
Forward Looking Statements
Except for any historical information, the matters discussed in this press release contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, including with respect to the Company’s product candidate’s potential to generate revenues and the expected timeframe for results of future studies. Words such as "expects," "anticipates," "intends," "plans," "believes," "seeks," "estimates" and similar expressions or variations of such words are intended to identify forward-looking statements. Although ZIVO believes there is a reasonable basis for each forward-looking statement, we caution you that these statements are based on a combination of facts and factors currently known by us and our expectations of the future, about which we cannot be certain. Our actual future results may be materially different from what we expect due to factors largely outside our control, including risks that our strategic partnerships may not facilitate the commercialization or market acceptance of our products; risks that we will be unable to increase production sufficient to meet demand; risks that our products may not be ready for commercialization in a timely manner or at all; risks that our products will not perform as expected based on results of our preclinical and clinical trials; our ability to raise additional funds; uncertainties inherent in the development process of our products; changes in regulatory requirements or decisions of regulatory authorities; the size and growth potential of the markets for our products; the results of clinical trials; our ability to protect our intellectual property rights; and other risks, uncertainties and assumptions, including those described under the heading “Risk Factors” in our filings with the Securities and Exchange Commission. These forward–looking statements speak only as of the date of this news release and ZIVO undertakes no obligation to revise or update any forward–looking statements for any reason, even if new information becomes available.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250620564330/en/
ZIVO Bioscience
Keith Marchiando, Chief Financial Officer
(248) 452-9866 x130
kmarchiando@zivobioscience.com
Alliance Advisors IR
Tirth T. Patel
(212) 201-6614
tpatel@allianceadvisors.com
Source: ZIVO Bioscience, Inc.
